MGMT methylation — secondary-GBM / IDH-mutant glioma progression context
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BIO-MGMT-METHYLATION-GLIOMA-SECONDARY |
|---|---|
| Type | Biomarker |
| Aliases | MGMT in IDH-mutant astrocytoma transformationMGMT methylation in secondary-GBM surveillancesecondary glioblastoma MGMTМетилювання MGMT — вторинна ГБМ / IDH-мутантна гліома, контекст прогресії |
| Status | reviewed 2026-05-18 |
| Diseases | None declared |
| Sources | SRC-EANO-GBM-2024 SRC-NCCN-CNS-2025 |
Biomarker Facts
| Biomarker type | methylation |
|---|---|
| Measurement | MethodMethylation-specific PCR (MSP) OR pyrosequencing OR EPIC methylation array on FFPE re-resection / re-biopsy sample at progression Unitscategorical: methylated | unmethylated |
| Related biomarkers | BIO-MGMT-METHYLATION BIO-IDH1-R132H |
Notes
STUB. Companion to BIO-MGMT-METHYLATION (primary-GBM treatment-selection scope). Surveillance use: IDH-mutant astrocytoma transformation to grade 4 / secondary GBM — MGMT status at progression informs second-line TMZ rechallenge vs lomustine vs trial. Distinction from primary entry is non-rigid (overlapping biology); kept as separate STUB so progression- context citations don't bleed into newly-diagnosed GBM rendering. Reviewer may merge with BIO-MGMT-METHYLATION if scope distinction is judged contrived.
Used By
No reverse references found in the YAML corpus.